Literature DB >> 30008323

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Daniel Zingg1, Julien Debbache1, Rodrigo Peña-Hernández2, Ana T Antunes1, Simon M Schaefer1, Phil F Cheng3, Dario Zimmerli4, Jessica Haeusel1, Raquel R Calçada5, Eylul Tuncer1, Yudong Zhang5, Raphaël Bossart1, Kwok-Kin Wong6, Konrad Basler4, Reinhard Dummer3, Raffaella Santoro7, Mitchell P Levesque3, Lukas Sommer8.   

Abstract

Human melanomas frequently harbor amplifications of EZH2. However, the contribution of EZH2 to melanoma formation has remained elusive. Taking advantage of murine melanoma models, we show that EZH2 drives tumorigenesis from benign BrafV600E- or NrasQ61K-expressing melanocytes by silencing of genes relevant for the integrity of the primary cilium, a signaling organelle projecting from the surface of vertebrate cells. Consequently, gain of EZH2 promotes loss of primary cilia in benign melanocytic lesions. In contrast, blockade of EZH2 activity evokes ciliogenesis and cilia-dependent growth inhibition in malignant melanoma. Finally, we demonstrate that loss of cilia enhances pro-tumorigenic WNT/β-catenin signaling, and is itself sufficient to drive metastatic melanoma in benign cells. Thus, primary cilia deconstruction is a key process in EZH2-driven melanomagenesis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EZH2; PRC2; WNT/β-catenin signaling; epigenetics; melanoma; metastasis; primary cilium; tumor initiation

Mesh:

Substances:

Year:  2018        PMID: 30008323     DOI: 10.1016/j.ccell.2018.06.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  48 in total

Review 1.  The primary cilium: Its role as a tumor suppressor organelle.

Authors:  Estanislao Peixoto; Seth Richard; Kishor Pant; Aalekhya Biswas; Sergio A Gradilone
Journal:  Biochem Pharmacol       Date:  2020-03-10       Impact factor: 5.858

Review 2.  Mixed signals from the cell's antennae: primary cilia in cancer.

Authors:  Thibaut Eguether; Michael Hahne
Journal:  EMBO Rep       Date:  2018-10-22       Impact factor: 8.807

3.  H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP.

Authors:  Chi Luo; Eduardo Balsa; Elizabeth A Perry; Jiaxin Liang; Clint D Tavares; Francisca Vazquez; Hans R Widlund; Pere Puigserver
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

4.  Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway.

Authors:  Wei Wang; Xia-Bo Shen; Da-Bing Huang; Wei Jia; Wen-Bin Liu; Yi-Fu He
Journal:  Cell Oncol (Dordr)       Date:  2019-06-29       Impact factor: 6.730

Review 5.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 6.  Mechanism and Regulation of Centriole and Cilium Biogenesis.

Authors:  David K Breslow; Andrew J Holland
Journal:  Annu Rev Biochem       Date:  2019-01-11       Impact factor: 23.643

7.  Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.

Authors:  François Kuonen; Noelle E Huskey; Gautam Shankar; Prajakta Jaju; Ramon J Whitson; Kerri E Rieger; Scott X Atwood; Kavita Y Sarin; Anthony E Oro
Journal:  J Invest Dermatol       Date:  2019-01-29       Impact factor: 8.551

8.  Primary Cilia Formation Does Not Rely on WNT/β-Catenin Signaling.

Authors:  Ondrej Bernatik; Petra Paclikova; Anna Kotrbova; Vitezslav Bryja; Lukas Cajanek
Journal:  Front Cell Dev Biol       Date:  2021-02-26

9.  Primary cilium and its role in tumorigenesis.

Authors:  Hongmei Mao; Yi Sun
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-04-25

10.  Exosomal miR-101-3p and miR-423-5p inhibit medulloblastoma tumorigenesis through targeting FOXP4 and EZH2.

Authors:  Ping Xue; Saihua Huang; Xiao Han; Caiyan Zhang; Lan Yang; Wenfeng Xiao; Jinrong Fu; Hao Li; Yufeng Zhou
Journal:  Cell Death Differ       Date:  2021-07-22       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.